Estrogens, Conjugated Tablet, Film Coated
Product Images NDC 50742-387

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Estrogens, Conjugated (NDC 50742-387). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ingenus Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0.3mg-1 (0.3mg 1)

Packaging label for Conjugated Estrogens Tablets USP 0.3 mg by Ingenus Pharmaceuticals, LLC. The film-coated oral tablets come in a bottle of 100 tablets. Label includes NDC 50742-387-01, storage instructions, dispensing information, and warnings. Manufactured in China.*

FDA Label Image

0.45mg-1 (0.45mg 1)

Label for Conjugated Estrogens Tablets, USP, 0.45 mg film-coated oral tablets by Ingenus Pharmaceuticals, LLC. The package contains 100 tablets. Storage instructions and warnings about dispensing and keeping medication out of children's reach are included. The label includes NDC 50742-388-01 and lot, expiration, and serial number placeholders.*

FDA Label Image

0.625mg-1 (0.625mg 1)

Label for Conjugated Estrogens Tablets, USP, 0.625 mg film-coated tablets by Ingenus Pharmaceuticals, LLC. The label indicates the product contains 100 tablets and includes handling and storage instructions, barcodes, and lot/expiration information.*

FDA Label Image

Table 5 (Table 5)

A data table titled 'Relative and Absolute Risk Seen in the Estrogen Alone Substudy of WHI' showing comparative risk values between conjugated estrogens (CE) and placebo for various medical events, including CHD events, stroke, deep vein thrombosis, pulmonary embolism, several cancers, fractures, total fractures, death due to other causes, overall mortality, and a global index. The table provides relative risk with 95% confidence intervals, absolute risk per 10,000 woman-years, and sample sizes for CE and placebo groups.*

FDA Label Image

Table 6 (Table 6)

A data table titled 'Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years.' It presents relative risk (with 95% confidence intervals) and absolute risk per 10,000 women-years for various health events comparing CE/MPA versus placebo groups in a clinical study, including cardiovascular events, cancers, fractures, and overall mortality.*

FDA Label Image

Figure1 (Figure1)

A cumulative percent curve chart illustrating the percent change from baseline in spine bone mineral density (BMD) among subjects. The chart compares four groups labeled as 0.625, 0.45, 0.3, and placebo, showing their respective cumulative percentages of subjects on the vertical axis against the percent change from baseline in spine BMD on the horizontal axis.*

FDA Label Image

Figure2 (Figure2)

A line graph showing the adjusted percent change from baseline over multiple cycles for three strengths (.3 mg, .45 mg, 0.625 mg) of conjugated estrogens and a placebo group. The x-axis represents the cycle number, and the y-axis shows the adjusted percent change. Each treatment group is represented by a different line with error bars indicating variability.*

FDA Label Image

Ingenus-logo-copy (Ingenus Logo Copy)

FDA Label Image

Ingenus-logo (Ingenus Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.